In our study of evaluable patients, CD30 CAR-Ts have a significant clinical activity in heavily pretreated r/r CD30+ lymphoma patients with ORR of 91.7% and CR rate of 50%. This evidence concerns the gene TNFRSF8 and lymphoma.